Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by husk16on Sep 08, 2013 5:27pm

230 Views

Post# 21725950

Re:Big Pharma Cut A Cheque For RVX

Sorry Schiff but that really wont help RVX. 5-10 million does not help the company. In order to do a small Phase 2 or a big Phase 3 we need a lot more money. That's why I think a partnership makes the most sense. IMO the data from ASSURE is good enough for someone to take the chance and help get RVX to FDA approval and production. You can agree or disagree with me on that. But let's see what happens.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale